Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

References

Page 1

	Year	Citations
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Nikhil C. Munshi, Larry D. Anderson, Nina Shah, New England Journal of Medicine	2021	2.3K
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Noopur Raje, Jesús G. Berdeja, Yi Lin, New England Journal of Medicine	2019	1.7K
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, The Lancet Hematological MalignancyCell TherapyImmunotherapyCiltacabtagene AutoleucelMedicine	2021	1.5K
A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study Michael Proctor, David Morrison, Dinesh Talwar, European Journal of Cancer InflammationPrognostic EvaluationPrognostic BiomarkersInflammation-based Prognostic ScoresMedicine	2011	734
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf, New England Journal of Medicine	2023	627
Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer Donald C. McMillan, J E M Crozier, Khalid Canna, International Journal of Colorectal Disease Prognostic EvaluationPatients Undergoing ResectionSurgical OncologyInflammation-based Prognostic ScoreColorectal Surgery	2007	523
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma Kai Rejeski, Ariel Perez Perez, Pierre Sesques, Blood	2021	398
Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2 Alastair O’Brien, James N. Fullerton, Karen A. Massey, Nature Medicine InflammationProstaglandin E2Autoimmune DiseaseHepatologyLiver Physiology	2014	282
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, Journal of Clinical Oncology	2023	257
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma María‐Victoria Mateos, Katja Weisel, Valerio De Stefano, Leukemia Relapsed/refractory MmCancer ManagementImmunologySurgeryPharmacotherapy	2022	225

Page 1